News

The MAA was filed in December 2016. An opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected in December of 2017, and decision is

Last month, the company had begun a phase 2 trial in the US for studying CTP-656 in patients with cystic fibrosis and having gating mutations. The phase 2 trial’s

The Phase 1b trial is intended to determine the maximum-tolerated dose of brontictuzumab in combination with trifluridine/tipiracil (Lonsurf).  The Phase 1b trial is designed to assess safety, preliminary

Gilead Research and Development executive vice president and chief scientific officer Norbert Bischofberger said: “Direct-acting antiviral treatments have transformed our ability to treat hepatitis C; however, for some

As part of the settlement and license agreement, all claims in the relevant legal proceedings will be dismissed, and the companies have granted certain patent rights to each

This multicenter trial is designed to assess the feasibility, safety and exploratory efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy.

The company specializes in the field of opioid addiction, emergency care and sterile injectables. By joining forces with Martindale Pharma, Ethypharm reinforces its presence in the UK. The

Abeona Therapeutics president & CEO Timothy Miller said: “This designation builds on our commercial portfolio of AAV gene therapies that have received FDA and EMA orphan drug designations, which is an

In addition, the FDA removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials. John Mendlein, PhD, CEO of aTyr Pharma, said: "This Fast